Emcure Pharmaceuticals Limited · NSE:EMCURE
Emcure Pharmaceuticals — Q4 FY26 Earnings Presentation
11 slides from Emcure Pharmaceuticals's earnings presentation, May 5, 2026
Slide 1: Exchange filing cover letter for results presentation
Emcure Ref: EPL/CS/SE/0039/2026 Date: May 05, 2026 To, National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, P J Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400 051 Mumbai- 400 001 Script Symbol: EMCURE Scrip Code/Symbol: 544210/ EMCURE Dear Sir/M
Slide 2: Results Q4 & FY26
Results Q4 & FY26 May 05, 2026 1
Slide 3: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute “forward-looking statements.” These statements are based on Emcure Pharmaceuticals Limited’s current expectations, assumptions, and projections about futur
Slide 4: FY26 - Performance Summary
FY26 - Performance Summary First year of our five-year strategic roadmap – delivered measurable results ✓ Crossed US$1 Bn revenue milestone, achieved above guidance 16.6% revenue growth ✓ 100 basis points base business1 EBITDA margin expansion ✓ Adjusted PAT growth of over 40% Strong momentum in Int
Slide 5: Q4 FY26 - Key Financial Snapshot
Q4FY26 Q4 FY26- Key - KeyFinancial FinancialSnapshot Snapshot ☷ Key Highlights – Q4FY26 Key Highlights Q4FY26 Revenue / Growth EBITDA / Margin Adj PAT1 / Margin ➢ Robust International Markets performance (revenue up 25.7% YoY); contribution at 60% 2,470 / 16.7% 485 / 19.7% 279 / 11.3% ➢ Domestic bus
Slide 6: FY26 - Key Financial Snapshot
Q4 FY26 FY26 - Key-Financial Key Financial Snapshot Snapshot ☷ Key Highlights – FY26 Revenue / Growth EBITDA / Margin Adi PAT1/ Margin ➢ Above guidance revenue growth of 16.6% led by robust performance in International markets 9,204 / 16.6% 1,789 / 19.4% 1,008/ 10.9% ➢ Domestic business grew in line
Slide 7: FY26 – Other Financial Data Points
FY26 – Other Financial Data Points R&D (₹ Cr) RoCE R&D as %of Revenue 4.4% 3.6% 4.2% 23.7% 384 22.0% 291 287 19.4% FY24 FY25 FY26 31-Mar-2024 31-Mar-2025 31-Mar-2026 CAPEX (₹ Cr) Net debt (₹ Cr) Net debt to 1.3 0.3 0.6 EBITDA (x) 434 376 1,558 276 Increased due to Zuventus 1,054 consolidation and Ma
Slide 8: FY26 - Domestic Business Performance
FY26 - Domestic Business Performance Domestic Revenue (₹ Cr) ➢ Growth in line with IPM. Continued productivity enhancement with PCPM increasing to 7.0 lacs in FY26 ➢ Strengthened the team with new leadership hires 4,027 across key segments as part of reforming and 3,660 3,144 reorganizing the domest
Slide 9: FY26 - International Business Performance
FY26 - International Business Performance Emerging Market (₹ Cr) Europe (₹ Cr) Canada (₹ Cr) 1,840 1,850 1,510 1,474 1,411 1,487 1,181 1,252 923 FY24 FY25 FY26 FY24 FY25 FY26 FY24 FY25 FY26 ➢ Balanced growth across both ARV1 ➢ Performance led by strong ➢ Healthy growth through market share and non-A
Slide 10: FY26 P&L Highlights
FY26 | P&L Highlights ₹ Cr except % Q4FY26 Q4FY25 YoY % Q3FY26 QoQ % FY26 FY25 YoY % Revenue from Operations 2,470 2,116 16.7% 2,363 4.5% 9,204 7,896 16.6% Domestic 977 929 5.2% 1,025 -4.6% 4,027 3,660 10.0% International 1,493 1,187 25.7% 1,339 11.5% 5,177 4,236 22.2% EM 556 481 15.5% 478 16.3% 1,8
Slide 11: For further information / institutional investor queries
For further information / institutional investor queries – Contact Investor.Relations@emcure.com Registered Office: Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C.,Hinjawadi Pune 411 057, Maharashtra, India Website: www.emcure.com 10
Emcure Pharmaceuticals — Q4 FY26 Earnings Presentation on 6ix